Close Menu

Proteome Sciences

The firms plan to offer an integrated biomarker services solution for pharmaceutical candidate development.

Movers & Shakers: Oct 8, 2010

Premium

Gregory Critchfield, Ian Pike, Rainer Metternich

Proteome Sciences had sued Sanofi-Aventis for breach of contract and statutory obligations in connection to a sales and transfer agreement which concerned a share and a limited partnership interest in Xzillion Proteomics.

Proteome Sciences plans to market the workflows as a discovery service performed out of its ISO-certified Frankfurt laboratory and will also use them to develop proprietary biomarker panels that it will commercialize for research and, eventually, clinical use.

The collaboration will combine Proteome Sciences' isobaric mass tagging reagents with Thermo Fisher's mass spectrometry systems.

The assays use multiple-reaction-monitoring mass spectrometry to measure the level of proteins associated with the disease and could be useful as diagnostic tests or research tools, said a company official.

The company said that the placing was intended to raise money for capital investment in equipment for its PS Biomarker Services division and to finance the further development of tandem mass tag-SRM mass spectrometry assays for its proprietary biomarkers.

The placing and an open offer could raise up to £6.9 million which would be used to see the company through to breakeven/profitability.

The firm claims the test can detect cancers as much as five years earlier than current testing methods.

The license agreement covers sales of the ProteoPrep kit line in Europe, Japan, and Australia.

Pages

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.